Review



cd19 apc ebioscience ilt2 pe  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Thermo Fisher cd19 apc ebioscience ilt2 pe
    Patient and tumor characteristics
    Cd19 Apc Ebioscience Ilt2 Pe, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19+apc+ebioscience+ilt2+pe/pmc06145700-140-17-18?v=Thermo+Fisher
    Average 86 stars, based on 1 article reviews
    cd19 apc ebioscience ilt2 pe - by Bioz Stars, 2026-08
    86/100 stars

    Images

    1) Product Images from "Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells"

    Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

    Journal: Oncotarget

    doi: 10.18632/oncotarget.26036

    Patient and tumor characteristics
    Figure Legend Snippet: Patient and tumor characteristics

    Techniques Used:

    ( A ) HLA-G expression in NMIBC biopsies. Two representative results obtained are shown. Brown labelling indicates HLA-G positivity. ( B ) Representative images of the results obtained for ILT2 cell-surface expression on CD8 + T cells from NMIBC patients with low (left) and high (right). Proportion of the ILT2-positive population within the CD8 + T cell population is indicated. ( C ) ILT2 expression levels on peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells for 25 healthy donors (HD), 20 aged-matched controls (Aged-matched), and 27 (for CD4 + T cells) or 76 (for CD8 + T cells) NMIBC patients. ( D ) Proportion of ILT2 + peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 12 months. ( E ) Proportion of ILT2 + peripheral CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 24 months. Mean and standard deviation are shown. P was calculated using Mann–Whitney test.
    Figure Legend Snippet: ( A ) HLA-G expression in NMIBC biopsies. Two representative results obtained are shown. Brown labelling indicates HLA-G positivity. ( B ) Representative images of the results obtained for ILT2 cell-surface expression on CD8 + T cells from NMIBC patients with low (left) and high (right). Proportion of the ILT2-positive population within the CD8 + T cell population is indicated. ( C ) ILT2 expression levels on peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells for 25 healthy donors (HD), 20 aged-matched controls (Aged-matched), and 27 (for CD4 + T cells) or 76 (for CD8 + T cells) NMIBC patients. ( D ) Proportion of ILT2 + peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 12 months. ( E ) Proportion of ILT2 + peripheral CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 24 months. Mean and standard deviation are shown. P was calculated using Mann–Whitney test.

    Techniques Used: Expressing, Standard Deviation, MANN-WHITNEY

    ( A ) Analysis for the whole cohort. ( B ) Analysis for incident patients. ( C ) Analysis for prevalent patients. Recurrence-free survival curves are shown for Low (≤18% CD8 + ILT2 + T cells among CD8 + T cells) vs intermediate (19%–45% CD8 + ILT2 + T cells among CD8 + T cells) vs high (≥46% CD8 + ILT2 + T cells among CD8 + T cells).
    Figure Legend Snippet: ( A ) Analysis for the whole cohort. ( B ) Analysis for incident patients. ( C ) Analysis for prevalent patients. Recurrence-free survival curves are shown for Low (≤18% CD8 + ILT2 + T cells among CD8 + T cells) vs intermediate (19%–45% CD8 + ILT2 + T cells among CD8 + T cells) vs high (≥46% CD8 + ILT2 + T cells among CD8 + T cells).

    Techniques Used:

    Cox regression for factors associated with tumor recurrence
    Figure Legend Snippet: Cox regression for factors associated with tumor recurrence

    Techniques Used: Isolation

    Calculation of the concordance index at different time points of the model with clinical variables alone, with CD8-ILT2 alone and with both clinical variables and CD8-ILT2
    Figure Legend Snippet: Calculation of the concordance index at different time points of the model with clinical variables alone, with CD8-ILT2 alone and with both clinical variables and CD8-ILT2

    Techniques Used:



    Similar Products

    cd19 apc ebioscience ilt2 pe  (Thermo Fisher)
    86
    Thermo Fisher cd19 apc ebioscience ilt2 pe
    Patient and tumor characteristics
    Cd19 Apc Ebioscience Ilt2 Pe, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd19+apc+ebioscience+ilt2+pe/pmc06145700-140-17-18?v=Thermo+Fisher
    Average 86 stars, based on 1 article reviews
    cd19 apc ebioscience ilt2 pe - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Patient and tumor characteristics

    Journal: Oncotarget

    Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

    doi: 10.18632/oncotarget.26036

    Figure Lengend Snippet: Patient and tumor characteristics

    Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

    Techniques:

    ( A ) HLA-G expression in NMIBC biopsies. Two representative results obtained are shown. Brown labelling indicates HLA-G positivity. ( B ) Representative images of the results obtained for ILT2 cell-surface expression on CD8 + T cells from NMIBC patients with low (left) and high (right). Proportion of the ILT2-positive population within the CD8 + T cell population is indicated. ( C ) ILT2 expression levels on peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells for 25 healthy donors (HD), 20 aged-matched controls (Aged-matched), and 27 (for CD4 + T cells) or 76 (for CD8 + T cells) NMIBC patients. ( D ) Proportion of ILT2 + peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 12 months. ( E ) Proportion of ILT2 + peripheral CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 24 months. Mean and standard deviation are shown. P was calculated using Mann–Whitney test.

    Journal: Oncotarget

    Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

    doi: 10.18632/oncotarget.26036

    Figure Lengend Snippet: ( A ) HLA-G expression in NMIBC biopsies. Two representative results obtained are shown. Brown labelling indicates HLA-G positivity. ( B ) Representative images of the results obtained for ILT2 cell-surface expression on CD8 + T cells from NMIBC patients with low (left) and high (right). Proportion of the ILT2-positive population within the CD8 + T cell population is indicated. ( C ) ILT2 expression levels on peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells for 25 healthy donors (HD), 20 aged-matched controls (Aged-matched), and 27 (for CD4 + T cells) or 76 (for CD8 + T cells) NMIBC patients. ( D ) Proportion of ILT2 + peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 12 months. ( E ) Proportion of ILT2 + peripheral CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 24 months. Mean and standard deviation are shown. P was calculated using Mann–Whitney test.

    Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

    Techniques: Expressing, Standard Deviation, MANN-WHITNEY

    ( A ) Analysis for the whole cohort. ( B ) Analysis for incident patients. ( C ) Analysis for prevalent patients. Recurrence-free survival curves are shown for Low (≤18% CD8 + ILT2 + T cells among CD8 + T cells) vs intermediate (19%–45% CD8 + ILT2 + T cells among CD8 + T cells) vs high (≥46% CD8 + ILT2 + T cells among CD8 + T cells).

    Journal: Oncotarget

    Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

    doi: 10.18632/oncotarget.26036

    Figure Lengend Snippet: ( A ) Analysis for the whole cohort. ( B ) Analysis for incident patients. ( C ) Analysis for prevalent patients. Recurrence-free survival curves are shown for Low (≤18% CD8 + ILT2 + T cells among CD8 + T cells) vs intermediate (19%–45% CD8 + ILT2 + T cells among CD8 + T cells) vs high (≥46% CD8 + ILT2 + T cells among CD8 + T cells).

    Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

    Techniques:

    Cox regression for factors associated with tumor recurrence

    Journal: Oncotarget

    Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

    doi: 10.18632/oncotarget.26036

    Figure Lengend Snippet: Cox regression for factors associated with tumor recurrence

    Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

    Techniques: Isolation

    Calculation of the concordance index at different time points of the model with clinical variables alone, with CD8-ILT2 alone and with both clinical variables and CD8-ILT2

    Journal: Oncotarget

    Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

    doi: 10.18632/oncotarget.26036

    Figure Lengend Snippet: Calculation of the concordance index at different time points of the model with clinical variables alone, with CD8-ILT2 alone and with both clinical variables and CD8-ILT2

    Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

    Techniques: